Quick Overview
- Keith Meister, ILMN director, offloaded $57.19 million worth of shares during a three-day period from September 2-4
- The genomics company will reenter the S&P 500 index on September 21, following its removal just 15 months earlier
- ILMN shares have surged 66.4% in 2024, currently hovering around $218 per share
- Recent quarterly results exceeded Wall Street forecasts, with revenue climbing 9.4% annually to $1.16 billion
- Analyst consensus leans toward Moderate Buy, though the $197.44 average target suggests potential 9.5% decline
According to SEC Form 4 filings, Illumina (ILMN) board member Keith Meister divested $57.19 million in company shares during the first week of September. The sales occurred across three trading sessions from September 2 through September 4, encompassing 263,560 shares at execution prices between approximately $213 and $221.55.
During Friday’s trading session, shares changed hands near $218.22, declining $3.44 intraday before rebounding almost 1% in after-hours activity following the announcement of the S&P 500 addition.
Meister executed these transactions through Corvex Management-controlled investment vehicles, where he holds the position of controlling general partner. Following these sales, his indirect stake stands at 770,350 shares, supplemented by 6,780 shares held directly. It’s worth noting that insider transactions can stem from various motivations, ranging from portfolio rebalancing to capturing gains.
According to TipRanks tracking data, company insiders have collectively sold $436.7 million worth of ILMN shares during the past 90 days, resulting in a Very Negative insider confidence rating for the stock.
S&P 500 Reentry Scheduled
Illumina will officially rejoin the prestigious S&P 500 index prior to market opening on September 21. The company will enter alongside Bloom Energy and Everpure, taking the spots vacated by Builders FirstSource, Molson Coors Beverage, and Trade Desk during the index’s quarterly reconstitution.
The index membership could trigger increased buying pressure for ILMN shares as passive funds and ETFs tracking the S&P 500 rebalance their portfolios accordingly. Index eligibility requires companies to maintain a minimum market capitalization of $22.7 billion while satisfying specific profitability, trading volume, and public float criteria.
This marks a comeback story for the genomics leader. Illumina exited the S&P 500 in June 2024 with shares languishing around $107. Today’s valuation represents a gain exceeding 100% from that low point.
Financial Performance and Wall Street Outlook
Illumina’s latest quarterly report, released July 30, revealed earnings per share of $1.31, surpassing the Street’s $1.23 projection. Top-line revenue reached $1.16 billion, representing 9.4% annual growth and beating the $1.13 billion consensus forecast. Management issued fiscal 2026 EPS guidance ranging from $5.30 to $5.40.
The company has delivered above-consensus earnings results for eight consecutive quarters.
Multiple investment banks increased their price objectives following the earnings release. Guggenheim elevated its target from $200 to $226, while Stifel Nicolaus boosted its forecast from $155 to $225. Piper Sandler established a $225 target, and JPMorgan raised its projection from $220 to $230 alongside an overweight recommendation.
Argus took the most bullish stance, upgrading shares to buy with a $235 price target.
Conversely, Zacks downgraded ILMN from strong buy to hold, expressing concerns about valuation following the stock’s substantial appreciation. The overall consensus tracked by MarketBeat stands at Hold, with an average target of $191.31, trading below current market levels.
ILMN’s 52-week trading range spans from $88.00 to $231.81. Institutional investors and hedge funds control 89.42% of outstanding shares.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
